Original Article
Hemoptysis Requiring Bronchial Artery Embolization in Pulmonary Arterial Hypertension
Abstract
Objectives: Hemoptysis is an uncommon complication in patients with pulmonary arterial hypertension (PAH). Although the mechanism of hemoptysis is unknown, treatment with bronchial artery embolization (BAE) is proposed to be a safe and reliable method of treatment. We report our experience in treating PAH patients presenting with acute hemoptysis that required multiple BAEs.
Methods: Three female and one male PAH patients, ages 45 ± 9 years (mean ± standard deviation [SD]) presented with acute hemoptysis. Right ventricular systolic pressure and cardiac index at the time of the first episode of hemoptysis were 85 ± 17 mm Hg and 2.7 ± 0.7 L/min/m2, respectively. Two of the four patients had recurrent episodes of hemoptysis, requiring multiple BAEs. All four were on intravenous prostacyclin analogue. None were receiving warfarin or endothelin receptor antagonists at the time of the episode. During each episode of hemoptysis, international normalized ratio (INR) was 1.09 ± 0.11 units, and platelet count was 124,000 ± 47,000 per microliter.
Results: Each episode of hemoptysis was acutely terminated with BAE. In the majority of cases, patients had multiple aberrant bronchial arteries embolized, and an average of 2.3 arteries was embolized per session (1-4 embolized arteries). Each BAE was performed utilizing polyvinyl alcohol particles, ranging from 250-500 microns. There were no reported complications of the 14 BAE procedures performed.
Conclusion: Although the incidence of hemoptysis is unknown and likely underreported, we report our experience in which recurrent hemoptysis was treated with multiple BAE procedures. This report emphasizes the efficacy and safety of BAE in terminating episodes of recurrent hemoptysis in patients with severe PAH.
Key Points
* Hemoptysis is an uncommon complication in patients with pulmonary arterial hypertension (PAH).
* Despite the availability of multiple registries of patients with PAH, the true incidence of clinically significant hemoptysis is unknown. Although it appears that hemoptysis may be a rare symptom in patients with PAH, it is likely that there is significant underreporting in the literature.
* Bronchial artery embolization appears to be highly successful in acute termination of hemoptysis, though it is not uncommon for a patient to have recurrent hemoptysis requiring re-embolization.
* Bronchial artery embolization is a safe and effective therapy for hemoptysis due to multiple etiologies, including PAH.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.